• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Compliance Actions and Activities

 
This page provides links, for example, to documents, lists, policies, programs, and statements relating to Compliance References used by FDA personnel:

Revisions

Revisions, Drafts, and Updates to ORA compliance references

 

Other Compliance Documents

  • Application Integrity Policy
    Regarding the integrity of data and information in applications submitted for FDA review and approval.
  • Bioresearch Monitoring Program
    (BIMO) of on-site inspections and data audits designed to monitor all aspects of the conduct and reporting of FDA regulated research.  The BIMO Program was established to assure the quality and integrity of data submitted to the agency in support of  new product approvals, as well as, to provide for protection of the rights and welfare of the thousands of human subjects involved in FDA regulated research.
  • NewClinical Investigator-Disqualification Proceedings
    FDA's new Clinical Investigator - Disqualification Proceedings database provides a list of clinical investigators who are or have been subject to an administrative clinical investigator disqualification action and indicates the current status of that action.  For each clinical investigator who is listed, links to related FDA regulatory documents (e.g., NIDPOEs, NOOHs, Presiding Officer Reports, Commissioner's Decisions) are provided, when available.
  • Electronic Records; Electronic Signatures, 21 CFR Part 11
    Background information and updates on the rule that allows the use of electronic records and electronic signatures for any  record that is required to be kept and maintained by other FDA regulations.
  • FDA Debarment List
    Firms or individuals convicted of a felony under Federal law for conduct (by a firm) relating to the development or approval, including the process for development or approval, of any abbreviated drug application; or (an individual convicted) for conduct relating to development or approval of any drug product, or otherwise relating to any drug product under the Federal Food, Drug, and Cosmetic Act.
  • Reading Room (Electronic Freedom of Information Act)
    ORA documents frequently requested by the public through the Freedom of Information Act.

 

-